JP2025503385A5 - - Google Patents

Info

Publication number
JP2025503385A5
JP2025503385A5 JP2024533005A JP2024533005A JP2025503385A5 JP 2025503385 A5 JP2025503385 A5 JP 2025503385A5 JP 2024533005 A JP2024533005 A JP 2024533005A JP 2024533005 A JP2024533005 A JP 2024533005A JP 2025503385 A5 JP2025503385 A5 JP 2025503385A5
Authority
JP
Japan
Prior art keywords
inhibitor
menin
menin inhibitor
moz
tki
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024533005A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503385A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/081587 external-priority patent/WO2023114867A2/en
Publication of JP2025503385A publication Critical patent/JP2025503385A/ja
Publication of JP2025503385A5 publication Critical patent/JP2025503385A5/ja
Pending legal-status Critical Current

Links

JP2024533005A 2021-12-15 2022-12-14 メニン－ｍｌｌエピジェネティック複合体を破壊することによる消化管間質腫瘍（ｇｉｓｔ）の治療的標的化 Pending JP2025503385A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163289943P 2021-12-15 2021-12-15
US63/289,943 2021-12-15
PCT/US2022/081587 WO2023114867A2 (en) 2021-12-15 2022-12-14 Therapeutic targeting of gastrointestinal stromal tumor (gist) by disrupting the menin-mll epigenetic complex

Publications (2)

Publication Number Publication Date
JP2025503385A JP2025503385A (ja) 2025-02-04
JP2025503385A5 true JP2025503385A5 (cg-RX-API-DMAC10.html) 2025-12-22

Family

ID=86773651

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024533005A Pending JP2025503385A (ja) 2021-12-15 2022-12-14 メニン－ｍｌｌエピジェネティック複合体を破壊することによる消化管間質腫瘍（ｇｉｓｔ）の治療的標的化

Country Status (10)

Country Link
US (1) US20250041299A1 (cg-RX-API-DMAC10.html)
EP (1) EP4447972A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025503385A (cg-RX-API-DMAC10.html)
KR (1) KR20240121720A (cg-RX-API-DMAC10.html)
CN (1) CN118234497A (cg-RX-API-DMAC10.html)
AU (1) AU2022410890A1 (cg-RX-API-DMAC10.html)
CA (1) CA3235383A1 (cg-RX-API-DMAC10.html)
IL (1) IL311862A (cg-RX-API-DMAC10.html)
MX (1) MX2024007201A (cg-RX-API-DMAC10.html)
WO (1) WO2023114867A2 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2831084T3 (es) 2016-06-10 2021-06-07 Vitae Pharmaceuticals Inc Inhibidores de la interacción menina-MLL
UY38988A (es) 2019-12-19 2021-06-30 Janssen Pharmaceutica Nv Derivados espiráncos sustituidos de cadena lineal
IL297039A (en) 2020-04-07 2022-12-01 Syndax Pharmaceuticals Inc Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof
US12187732B2 (en) 2022-03-28 2025-01-07 Isosterix, Inc. Inhibitors of the myst family of lysine acetyl transferases
AR132185A1 (es) 2023-03-24 2025-06-04 Acerta Pharma Bv COMPUESTOS DE 1-H-PIRROLO[2,3-c]PIRIDINA
JP2026525148A (ja) * 2023-07-17 2026-07-29 クラ オンコロジー，インク． メニン阻害剤を含む医薬組成物
IL325861A (en) 2023-07-17 2026-03-01 Kura Oncology Inc Crystalline forms of a menin inhibitor
KR20260099138A (ko) * 2023-10-20 2026-06-26 얀센 파마슈티카 엔브이 암 치료에 사용하기 위한, (r)-n-에틸-5-플루오로-n-아이소프로필-2-((5-(2-(6-((2-메톡시에틸)(메틸)아미노)-2-메틸헥산-3-일)-2,6-다이아자스피로[3.4]옥탄-6-일)-1,2,4-트라이아진-6-일)옥시)벤즈아미드, 이의 제제 및 이의 투여 요법
IL328224A (en) * 2023-11-17 2026-07-01 Kura Oncology Inc Methods for treating KIT-positive cancer with a menin inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016197027A1 (en) * 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
US10752639B2 (en) * 2016-03-16 2020-08-25 Kura Oncology, Inc. Bridged bicyclic inhibitors of menin-MLL and methods of use
WO2017161028A1 (en) * 2016-03-16 2017-09-21 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use
JP2022503792A (ja) * 2018-09-26 2022-01-12 クラ オンコロジー，インク． メニン阻害剤を用いた血液悪性腫瘍の処置

Similar Documents

Publication Publication Date Title
ES2900829T3 (es) Terapia combinada para el tratamiento del cáncer
US9486445B2 (en) Combination therapy for proliferative disorders
US20080032989A1 (en) Method of treating inflammatory diseases using tyroskine kinase inhibitors
JP2007529421A5 (cg-RX-API-DMAC10.html)
EP4110326B1 (en) Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
JP2014065696A5 (cg-RX-API-DMAC10.html)
TWI762784B (zh) Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途
EP4054579A1 (en) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CN1282248A (zh) 阳萎的联合治疗
WO2022106711A1 (en) Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
CN118201615A (zh) 喹唑啉酮化合物用于治疗癌症的新用途
KR20240112932A (ko) 암 치료를 위한 cdk2 억제제 및 cdk4 억제제를 포함하는 방법 및 투여 섭생법
CN104349779A (zh) Pi-3激酶抑制剂的剂量方案
WO2021063332A1 (zh) 一种ezh2抑制剂与cdk4/6抑制剂联合在制备治疗肿瘤药物中的用途
WO2018170447A1 (en) Combination therapies for the treatment of breast cancer
JP2023510426A (ja) 癌を治療するための上皮細胞増殖因子受容体チロシンキナーゼ阻害剤
CN120713908A (zh) 帕布昔利布在黏膜恶性黑色素瘤中的应用
JP2025516647A (ja) Ｌｓｄ１阻害薬を用いる悪性末梢神経鞘腫（ｍｐｎｓｔ）の治療法
JP2022533251A (ja) 患者において血清リン酸塩を低下させるための組み合わせ
JPWO2005009444A1 (ja) 医薬組成物
JP2007505859A (ja) イマチニブおよびミドスタウリンでの消化管間質腫瘍の処置
WO2025026376A1 (zh) 用于治疗肿瘤疾病的EGFR激酶抑制剂和c-Met激酶抑制剂的药物组合
CN121130092A (zh) 抗hiv药物在抑制非小细胞肺癌耐药中的应用
EP3124025A1 (fr) Association entre le 3-[(3-{[4-(4-morpholinylméthyl)-1h-pyrrol-2-yl]méthylène}-2-oxo-2,3-dihydro-1h-indol-5-yl)méthyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr
WO2023011415A1 (zh) Egfr抑制剂的药物组合及其应用